Bioxyne Limited (ASX:BXN)
Australia
· Delayed Price · Currency is AUD 0.0540
-0.0050 (-8.47%)
Mar 9, 2026, 4:10 PM AEST
Bioxyne Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 47.18 | 28.43 | 9.33 | 5.15 | 0.46 | 2.11 | Upgrade
|
| Other Revenue | 0.78 | 0.85 | 0.32 | 0.14 | - | 0.09 | Upgrade
|
| Revenue | 47.95 | 29.28 | 9.64 | 5.3 | 0.46 | 2.2 | Upgrade
|
| Revenue Growth (YoY) | 178.16% | 203.66% | 81.97% | 1042.88% | -78.97% | -5.61% | Upgrade
|
| Cost of Revenue | 28.27 | 18.1 | 5.93 | 3.73 | 0.33 | 1.25 | Upgrade
|
| Gross Profit | 19.69 | 11.18 | 3.72 | 1.57 | 0.13 | 0.95 | Upgrade
|
| Selling, General & Admin | 7.29 | 4.23 | 3.64 | 2.69 | 0.49 | 1.19 | Upgrade
|
| Research & Development | 0.17 | 0.17 | 0.72 | - | - | 0.09 | Upgrade
|
| Operating Expenses | 9.78 | 6.08 | 4.85 | 3.38 | 0.59 | 1.32 | Upgrade
|
| Operating Income | 9.91 | 5.1 | -1.13 | -1.82 | -0.45 | -0.37 | Upgrade
|
| Interest Expense | -0.04 | - | - | - | - | -0 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.02 | 0 | - | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.04 | 0 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.69 | -0.22 | -0.21 | -0.04 | -0 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | 9.2 | 4.9 | -1.32 | -1.82 | -0.45 | -0.5 | Upgrade
|
| Impairment of Goodwill | - | - | -11.57 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0.08 | - | - | - | Upgrade
|
| Asset Writedown | -0.26 | - | - | -0.1 | -0.04 | - | Upgrade
|
| Pretax Income | 8.94 | 4.9 | -12.97 | -1.92 | -0.49 | -0.5 | Upgrade
|
| Earnings From Continuing Operations | 8.94 | 4.9 | -12.97 | -1.92 | -0.49 | -0.5 | Upgrade
|
| Earnings From Discontinued Operations | 0.04 | - | -0.53 | -0.05 | - | - | Upgrade
|
| Net Income to Company | 8.99 | 4.9 | -13.5 | -1.96 | -0.49 | -0.5 | Upgrade
|
| Minority Interest in Earnings | -0.02 | - | 0.18 | 0.02 | - | - | Upgrade
|
| Net Income | 8.97 | 4.9 | -13.33 | -1.94 | -0.49 | -0.5 | Upgrade
|
| Net Income to Common | 8.97 | 4.9 | -13.33 | -1.94 | -0.49 | -0.5 | Upgrade
|
| Net Income Growth | 300.76% | - | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 2,120 | 2,078 | 1,930 | 1,344 | 732 | 640 | Upgrade
|
| Shares Outstanding (Diluted) | 2,259 | 2,150 | 1,930 | 1,344 | 732 | 640 | Upgrade
|
| Shares Change (YoY) | 11.95% | 11.36% | 43.61% | 83.52% | 14.42% | - | Upgrade
|
| EPS (Basic) | 0.00 | 0.00 | -0.01 | -0.00 | -0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | 0.00 | 0.00 | -0.01 | -0.00 | -0.00 | -0.00 | Upgrade
|
| EPS Growth | 259.93% | - | - | - | - | - | Upgrade
|
| Free Cash Flow | 0.28 | 4.21 | -3.74 | -1.19 | -0.57 | 0.05 | Upgrade
|
| Free Cash Flow Per Share | - | 0.00 | -0.00 | -0.00 | -0.00 | - | Upgrade
|
| Gross Margin | 41.05% | 38.17% | 38.53% | 29.55% | 29.10% | 43.13% | Upgrade
|
| Operating Margin | 20.66% | 17.41% | -11.75% | -34.32% | -97.72% | -16.97% | Upgrade
|
| Profit Margin | 18.70% | 16.74% | -138.19% | -36.61% | -106.55% | -22.49% | Upgrade
|
| Free Cash Flow Margin | 0.59% | 14.37% | -38.77% | -22.45% | -122.27% | 2.41% | Upgrade
|
| EBITDA | 10.2 | 5.4 | -1.08 | -1.71 | -0.42 | -0.36 | Upgrade
|
| EBITDA Margin | 21.27% | 18.45% | -11.22% | -32.25% | -91.09% | -16.17% | Upgrade
|
| D&A For EBITDA | 0.29 | 0.3 | 0.05 | 0.11 | 0.03 | 0.02 | Upgrade
|
| EBIT | 9.91 | 5.1 | -1.13 | -1.82 | -0.45 | -0.37 | Upgrade
|
| EBIT Margin | 20.66% | 17.41% | -11.75% | -34.32% | -97.72% | -16.97% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.